Nanomedicines for treatment of viral diseases

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 30, Issue 1, 2013, Pages 1-49

  Mehendale, Rujuta ^a   Joshi, Medha ^b   Patravale, Vandana ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Nanocarriers; Nanoparticles; Targated drug delivery; Viral diseases

Indexed keywords

ACICLOVIR; ADEFOVIR DIPIVOXIL; CELL PENETRATING PEPTIDE; CGP 57813; CGP 70726; CHITOSAN DERIVATIVE; CURCUMIN; DELAVIRDINE; DENDRIMER; DIDANOSINE; EFAVIRENZ; GANCICLOVIR; GOLD NANOPARTICLE; IMMUNOLIPOSOME; INDINAVIR; LAMIVUDINE; LECTIN RECEPTOR; LIPOSOME; LOPINAVIR; NANOCARRIER; NEVIRAPINE; NIOSOME; RIBAVIRIN; RILPIVIRINE; RITONAVIR; SAQUINAVIR; SOLID LIPID NANOPARTICLE; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIVAGEL; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG FORMULATION; DRUG TARGETING; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NANOEMULSION; NANOMEDICINE; NONHUMAN; RETICULOENDOTHELIAL SYSTEM; SINGLE DRUG DOSE; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; DRUG CARRIERS; HUMANS; NANOMEDICINE; NANOPARTICLES; VIRUS DISEASES;

EID: 84875060324     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2013005469     Document Type: Article

References (170)

1. Rollinger JM, Steindl TM, Schuster D, Kirchmair J, Anrain K, Ellmerer EP, Langer T, Stuppner H, Wutzler P, Schmidtke M. Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. J Med Chem. 2008;51(4):842-51.
2. Matteucci ML, Thrall DE. The role of liposomes in drug delivery and diagnostic imaging: a review Veterinary Radiology & Ultrasound. 2000;41(2):100-7.
3. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. [10.1038/nrd1632]. 2005;4(2):145-60.
4. Mukherjee B, Patra B, Layek B, Mukherjee A. Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study. Int J Nanomed. 2007;2(2):213-25.
5. Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdisciplinary Reviews: Nanomed Nanobiotechnol. 2012;4(2):219-33.
6. Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol. 1991;146(12):4234-41.
7. Koff WC, Fidler IJ. The potential use of liposome-mediated antiviral therapy. Antiviral Res. 1985;5(3):179-90.
8. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 2006;1(3):297-315.
9. Lembo D, Cavalli R. Nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother. 2010;21(2):53-70.
10. Gilbert BE, Knight V. Pulmonary delivery of antiviral drugs in liposome aerosols. Semin Ped Inf Dis. 1996;7(2):148-54.
11. Peyman GA, Khoobehi B, Tawakol M, Schulman JA, Mortada HA, Alkan H, Fiscella R. Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina. 1987;7(4):227-9.
12. Ebrahim S, Peyman GA, Lee PJ. Applications of Liposomes in Ophthalmology. Surv Ophthalmol. 2005;50(2):167-82.
13. Pollock S, Nichita NB, Bohmer A, Radulescu C, Dwek RA, Zitzmann N. Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17176-81.
14. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood. 2006 October 15, 2006;108(8):2827-35.
15. Dou H, Morehead J, Destache CJ, Kingsley JD, Shlyakhtenko L, Zhou Y, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology. 2007;358(1):148-58.
16. Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol. 2009 Jul 1;183(1):661-9.
17. Phillips N, Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood. 1992 March 1, 1992;79(5):1137-43.
18. Phillips NC. Stimulation of Kupffer cell tumoricidal activity by liposomal muramyl dipeptides. Res Immunol. 1992 Feb;143(2):205-10.
19. Phillips NC, Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood. 1992 Mar 1;79(5):1137-43.
20. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006 Mar;2(1):8-21.
21. Khalil NM, Carraro E, Cotica LF, Mainardes RM. Potential of polymeric nanoparticles in AIDS treatment and prevention. Expert Opin Drug Deliv. 2011 Jan;8(1):95-112.
22. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res. 2009 May;26(5):1025-58.
23. Bapat N, Boroujerdi M. Uptake capacity and adsorption isotherms of doxorubicin on polymeric nanoparticles: effect of methods of preparation. Drug Devel Ind Pharm. 1992;18(1):65-77.
24. Gupta U, Jain NK. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Del Rev. 2010;62(4-5):478-90.
25. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Current Opin Solid State Mat Sci. 2002;6(4):319-27.
26. Meijer DK, Jansen RW, Molema G. Drug targeting systems for antiviral agents: options and limitations. Antiviral Res. 1992;18(3-4):215-58.
27. Shah L, Amiji M. Intracellular Delivery of Saquinavir in Biodegradable Polymeric Nanoparticles for HIV/AIDS. Pharm Res. 2006;23(11):2638-45.
28. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988;85(18):6949-53.
29. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996;13(12):1838-45.
30. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Fiamengo SA, Neuwelt EA. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery. 1998;43(4):879-86; discussion 86-9.
31. Lanao JM, Briones E, Colino CI. Recent advances in delivery systems for anti-HIV1 therapy. J Drug Target. 2007;15(1):21-36.
32. Mallipeddi R, Rohan LC. Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv. 2010 Jan;7(1):37-48.
33. Govender T, Ojewole E, Naidoo P, Mackraj I. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv. 2008 Nov;15(8):493-501.
34. Dembri A, Montisci MJ, Gantier JC, Chacun H, Ponchel G. Targeting of 3'-azido 3'-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. Pharm Res. 2001 Apr;18(4):467-73.
35. Schäfer V, von Briesen H, Andreesen R, Steffan A-M, Royer C, Tröster S, Kreuter J, Rübsamen-Waigmann H. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm Res. 1992;9(4):541-6.
36. Löbenberg R, Araujo L, Kreuter J. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur J Pharm Biopharm. 1997;44(2):127-32.
37. Löbenberg R, Araujo L, von Briesen H, Rodgers E, Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Rel. 1998;50(1-3):21-30.
38. De Jaeghere F, Allémann E, Kubel F, Galli B, Cozens R, Doelker E, Gurny R. Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J Control Rel. 2000;68(2): 291-8.
39. Leroux J-C, Doelker E, Gurny R, Cozens R, Roesel JL, Galli B, Kubel F, Doelker E, Gurny R. Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J Pharm Sci. 1995;84(12):1387-91.
40. Ham A, Cost M, Sassi A, Dezzutti C, Rohan L. Targeted Delivery of PSC-RANTES for HIV-1 Prevention using biodegradable nanoparticles. Pharm Res. 2009;26(3):502-11.
41. Bender AR, von Briesen H, Kreuter J, Duncan IB, Rübsamen-Waigmann H. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicro Agents Chemother. 1996 June 1, 1996;40(6):1467-71.
42. Kuo Y-C, Chen H-H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int J Pharm. 2006;327(1-2):160-9.
43. Kuo Y-C, Su F-L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm. 2007;340(1-2):143-52.
44. Kuo Y-C, Yu H-W. Transport of saquinavir across human brain-microvascular endothelial cells by poly(lactide-co-glycolide) nanoparticles with surface poly-(γ-glutamic acid). Int J Pharm. 2011;416(1):365-75.
45. Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, Dash A. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis. 2009;9:198.
46. Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA. Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother. 2010 Oct;65(10):2183-7.
47. Bender A, Schafer V, Steffan AM, Royer C, Kreuter J, Rubsamen-Waigmann H, von Briesen H. Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles. Res Virol. 1994;145(3-4):215-20.
48. Gandapu U, Chaitanya RK, Kishore G, Reddy RC, Kondapi AK. Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. PLoS ONE. 2011;6(8):e23388.
49. Joung Y, Son S, Jang J, Kwon M, Park K. Sustained cytoplasmic delivery and anti-viral effect of PLGA nanoparticles carrying a nucleic acid-hydrolyzing monoclonal antibody. Pharm Res.1-11.
50. Gajbhiye V, Palanirajan VK, Tekade RK, Jain NK. Dendrimers as therapeutic agents: a systematic review. J Pharm Pharmacol. 2009;61(8):989-1003.
51. Mintzer MA, Grinstaff MW. Biomedical applications of dendrimers: a tutorial. Chem Soc Rev. 2011;40(1).
52. Wang W, Guo Z, Chen Y, Liu T, Jiang L. Influence of Generation 2-5 of PAMAM Dendrimer on the Inhibition of Tat Peptide/ TAR RNA Binding in HIV-1 Transcription. Chem Biol Drug Design. 2006;68(6):314-8.
53. Agarwal A, Asthana A, Gupta U, Jain NK. Tumour and dendrimers: a review on drug delivery aspects. J Pharm Pharmacol. 2008;60(6):671-88.
54. Rojo J, Delgado R. Glycodendritic structures: promising new antiviral drugs. J Antimicrob Chemother. 2004 September 2004;54(3):579-81.
55. Konda SD, Wang S, Brechniel M, Wiener EC. Biodistribution of a 153Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest Radiol. 2002;37(4):199-204.
56. Ali MM, Woods M, Caravan P, Opina ACL, Spiller M, Fettinger JC, Sherry AD. Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent. Chem-A Eur J. 2008;14(24):7250-8.
57. Kim PS, Read SW. Nanotechnology and HIV: potential applications for treatment and prevention. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2010;2(6):693-702.
58. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. AdvDrug Deliv Rev. 2010;62(4-5):491-502.
59. Reuter JD, Myc A, Hayes MM, Gan Z, Roy R, Qin D, Yin R, Piehler LT, Esfand R, Tomalia DA, Baker JR Jr. Inhibition of viral adhesion and infection by sialic-acid-conjugated dendritic polymers. Bioconjugate Chem. 1999 1999/03/01;10(2):271-8.
60. Oka H, Onaga T, Koyama T, Guo C-T, Suzuki Y, Esumi Y, Hatano K, Terunuma D, Matsuoka K. Syntheses and biological evaluations of carbosilane dendrimers uniformly functionalized with sialyl α(2→3) lactose moieties as inhibitors for human influenza viruses. Bioorg Med Chem. 2009;17(15):5465-75.
61. Landers JJ, Cao Z, Lee I, Piehler LT, Myc PP, Myc A, Hamouda T, Galecki AT, Baker JR Jr. Prevention of influenza pneumonitis by sialic acid-conjugated dendritic polymers. J Infect Dis. 2002 Nov 1;186(9):1222-30.
62. Barnard DL, Sidwell RW, Gage TL, Okleberry KM, Matthews B, Holan G. Anti-respiratory syncytial virus activity of dendrimer polyanions. Antiviral Res. 1997;34(2):88-
63. Gazumyan A, Mitsner B, Ellestad GA. Novel anti-RSV dianionic dendrimer-like compounds: design, synthesis and biological evaluation. Curr Pharm Des. 2000;6(5):525-46.
64. Macri RV, Karlovská J, Doncel GF, Du X, Maisuria BB, Williams AA, Sugandhi EW, Falkinham JO 3rd, Esker AR, Gandour RD. Comparing anti-HIV, antibacterial, antifungal, micellar, and cytotoxic properties of tricarboxylato dendritic amphiphiles. Bioorgan Med Chem. 2009;17(8):3162-8.
65. Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomed. 2007;2(4):561-6.
66. Witvrouw M, Fikkert V, Pluymers W, Matthews B, Mardel K, Schols D, Raff J, Debyser Z, De Clercq E, Holan G, Pannecouque C. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Molec Pharm. 2000 November 1, 2000;58(5):1100-8.
67. Dezzutti CS, James VN, Ramos A, Sullivan ST, Siddig A, Bush TJ, Grohskopf LA, Paxton L, Subbarao S, Hart CE. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother. 2004 October 1, 2004;48(10):3834-44.
68. Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta. 2007 Apr;1770(4):681-6.
69. Telwatte S, Moore K, Johnson A, Tyssen D, Sterjovski J, Aldunate M, Gorry PR, Ramsland PA, Lewis GR, Paull JR, Sonza S, Tachedjian G. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Res. 2011 Jun;90(3):195-9.
70. Jiang YH, Emau P, Cairns JS, Flanary L, Morton WR, McCarthy TD, Tsai CC. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in Macaques. AIDS Res Hum Retrovirus. 2005;21(3):207-13.
71. Gong Y, Matthews B, Cheung D, Tam T, Gadawski I, Leung D, Holan G, Raff J, Sacks S. Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication. Antiviral Res. 2002 Aug;55(2):319-29.
72. Bernstein DI, Stanberry LR, Sacks S, Ayisi NK, Gong YH, Ireland J, Mumper RJ, Holan G, Matthews B, McCarthy T, Bourne N. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother. 2003 December 1, 2003;47(12):3784-8.
73. Gong E, Matthews B, McCarthy T, Chu J, Holan G, Raff J, Sacks S. Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antiviral Res. 2005;68(3):139-46.
74. Mallipeddi R, Rohan LC. Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomed. 2010;5:533-47.
75. Blanzat M, Turrin CO, Aubertin AM, Couturier-Vidal C, Caminade AM, Majoral JP, Rico-Lattes I, Lattes A. Dendritic catanionic assemblies: in vitro anti-HIV activity of phosphorus-containing dendrimers bearing galbeta1cer analogues. Chembiochem. 2005 Dec;6(12):2207-13.
76. Bourne N, Stanberry LR, Kern ER, Holan G, Matthews B, Bernstein DI. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother. 2000 Sep;44(9):2471-4.
77. Tyssen D, Henderson SA, Johnson A, Sterjovski J, Moore K, La J, Zanin M, Sonza S, Karellas P, Giannis MP, Krippner G, Wesselingh S, McCarthy T, Gorry PR, Ramsland PA, Cone R, Paull JRA, Lewis GR, Tachedjian G. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS ONE. 2010;5(8):e12309.
78. Zhou J, Neff CP, Liu X, Zhang J, Li H, Smith DD, Swiderski P, Aboellail T, Huang Y, Du Q, Liang Z, Peng L, Akkina R, Rossi JJ. Systemic administration of combinatorial dsirnas via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther. 2011;19(12):2228-38.
79. McCarthy TD, Karellas P, Henderson SA, Giannis M, O'Keefe DF, Heery G, Paull JR, Matthews BR, Holan G. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Molec Pharm. 2005 2005/08/01;2(4):312-8.
80. du Toit LC, Pillay V, Choonara YE. Nano-microbicides: Challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS. Adv Drug Delivery Rev. 2010;62(4-5):532-46.
81. Dutta T, Agashe HB, Garg M, Balakrishnan P, Kabra M, Jain NK. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target. 2007 Jan;15(1):89-98.
82. Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev. 2010;62(4-5):503-17.
83. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: Let's meet the challenge. International J Pharm. 2010;394(1-2):122-42.
84. Lai F, Sinico C, De Logu A, Zaru M, Müller RH, Fadda AM. SLN as a topical delivery system for Artemisia arborescens essential oil: In vitro antiviral activity and skin permeation study. Int J Nanomed. 2007;2(3):419-25.
85. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008 Apr 21;127(2):97-109.
86. Chattopadhyay N, Zastre J, Wong H-L, Wu X, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res. 2008;25(10):2262-71.
87. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):165-96.
88. Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009 Feb;71(2):161-72.
89. Heiati H, Tawashi R, Shivers RR, Phillips NC. Solid lipid nanoparticles as drug carriers. I. Incorporation and retention of the lipophilic prodrug 3-azido-3-deoxythymidine palmitate. Int J Pharm. 1997;146(1):123-31.
90. Fang J-Y, Fang C-L, Liu C-H, Su Y-H. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70(2):633-40.
91. Heiati H, Tawashi R, Shivers RR, Phillips NC. Solid lipid nanoparticles as drug carriers I. Incorporation and retention of the lipophilic prodrug 3'-azido-3'-deoxythymidine palmitate. Int J Pharm. 1997;146(1):123-31.
92. Heiati H, Tawashi R, Phillips NC. Solid lipid nanoparticles as drug carriers: II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3-azido-3-deoxythymidine palmitate in mice. Int J Pharm. 1998;174(1-2):71-80.
93. Zhang XG, Miao J, Li MW, Jiang SP, Hu FQ, Du YZ. Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy. J Zhejiang Univ Sci B. 2008 Jun;9(6):506-10.
94. Choi S-U, Bui T, Ho RJY. pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J Pharm Sci. 2008;97(2):931-43.
95. Kuo Y-C, Chung C-Y. Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Colloids and Surfaces B: Biointerfaces. 2011;88(2):682-90.
96. Kuo Y-C, Chen H-H. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int J Pharm. 2009;365(1-2):206-13.
97. Kuo Y-C, Kuo C-Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int J Pharm. 2008;351(1-2):271-81.
98. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004 Jul;56(7):827-40.
99. van't Klooster G, Hoeben E, Borghys H, Looszova A, Bouche M-P, van Velsen F, Baert L. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother. 2010 MAY 2010;54(5):2042-50.
100. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004 Sep;3(9):785-96.
101. Behrens I, Pena AIV, Alonso MJ, Kissel T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm Res. 2002;19(8):1185-93.
102. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev. 2001;50(1-2):81-106.
103. Shegokar R, Singh KK. Nevirapine nanosuspensions for HIV reservoir targeting. Die Pharmazie: An International Journal of Pharmaceutical Sciences. 2011;66(6):408-15.
104. Shegokar R, Singh KK. Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation. Int J Pharm. 2011;421(2):341-52.
105. Shegokar R, Jansch M, Singh KK, Müller RH. In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy. Nanomed Nanotechnol Biol Med. 2011;7(3):333-40.
106. Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, Mosley RL, Ma Z, Graham S, Chaubal M, Werling J, Rabinow B, Dou H, Gendelman HE. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond). 2009 Dec;4(8):903-17.
107. Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, Gendelman HE. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol. 2010 Dec;5(4):592-601.
108. Nowacek AS, Balkundi S, McMillan J, Roy U, Martinez-Skinner A, Mosley RL, Kanmogne G, Kabanov AV, Bronich T, Gendelman HE. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release. 2011 Mar 10;150(2):204-11.
109. Fadeel B, Garcia-Bennett AE. Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev. 2010;62(3):362-74.
110. Galdiero S, Falanga A, Vitiello M, Cantisani M, Marra V, Galdiero M. Silver Nanoparticles as potential antiviral agents. Molecules. 2011;16(10):8894-918.
111. Xu ZP, Zeng QH, Lu GQ, Yu AB. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Engin Sci. 2006;61(3):1027-40.
112. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters. Int J Oncol. 2000 Aug;17(2):309-15.
113. Pouton CW, Seymour LW. Key issues in non-viral gene delivery. Adv Drug Deliv Rev. 2001;46(1-3):187-203.
114. Baram-Pinto D, Shukla S, Gedanken A, Sarid R. Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles. Small. 2010 May 7;6(9):1044-50.
115. Baram-Pinto D, Shukla S, Perkas N, Gedanken A, Sarid R. Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate. Bioconjug Chem. 2009 Aug 19;20(8):1497-502.
116. Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology. 2010;8:1.
117. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology. 2005;3:6.
118. Rogers JV, Parkinson CV, Choi YW, Speshock JL, Hussain SM. A preliminary assessment of silver nanoparticles inhibition of monkeypox virus plaque. Nanoscale Res Lett. 2008;3:129-33.
119. Speshock JL, Murdock RC, Braydich-Stolle LK, Schrand AM, Hussain SM. Interaction of silver nanoparticles with Tacaribe virus. J Nanobiotechnol. 2010;8:19.
120. Lu L, Sun RW, Chen R, Hui CK, Ho CM, Luk JM, Lau GK, Che CM. Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther. 2008;13(2):253-62.
121. Sun RW, Chen R, Chung NP, Ho CM, Lin CL, Che CM. Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem Commun (Camb). 2005 Oct 28(40):5059-61.
122. Sawada H, Narumi T, Kiyohara M, Baba M. Preparation of fluoroalkyl end-capped cooligomers/silica nanoparticles: A new approach to fluorinated nanoparticle inhibitors of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus (SIVmac). J Fluor Chem. 2007;128(11):1416-20.
123. You J, Zhang Y, Hu Z. Bacteria and bacteriophage inactivation by silver and zinc oxide nanoparticles. Colloids Surf B Biointerfaces. 2011 Jul 1;85(2):161-7.
124. Ren G, Hu D, Cheng EWC, Vargas-Reus MA, Reip P, Allaker RP. Characterisation of copper oxide nanoparticles for antimicrobial applications. Int JAntimicrob Agents. 2009;33(6):587-90.
125. Anton N, Benoit J-P, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-A review. J Control Rel. 2008;128(3):185-99.
126. Izquierdo P, Esquena J, Tadros TF, Dederen C, Garcia MJ, Azemar N, Solans C. Formation and stability of nano-emulsions prepared using the phase inversion temperature method. Langmuir. 2001 2002/01/01;18(1):26-30.
127. Schwarz JC, Klang V, Karall S, Mahrhauser D, Resch GP, Valenta C. Optimisation of multiple W/O/W nanoemulsions for dermal delivery of aciclovir. Int J Pharm. (0).
128. Donovan BW, Reuter JD, Cao Z, Myc A, Johnson KJ, Baker JR, Jr. Prevention of murine influenza A virus pneumonitis by surfactant nano-emulsions. Antivir Chem Chemother. 2000 Jan;11(1):41-9.
129. Chepurnov AA, Bakulina LF, Dadaeva AA, Ustinova EN, Chepurnova TS, Baker JR, Jr. Inactivation of Ebola virus with a surfactant nanoemulsion. Acta Trop. 2003 Aug;87(3):315-20.
130. Vyas TK, Shahiwala A, Amiji MM. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm. 2008 Jan 22;347(1-2):93-101.
131. Handjani-Vila RM, Ribier A, Rondot B, Vanlerberghie G. Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int J Cosmet Sci. 1979 Oct;1(5):303-14.
132. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Rel. 1994;30(1):1-15.
133. Muzzalupo R, Tavano L, Cassano R, Trombino S, Ferrarelli T, Picci N. A new approach for the evaluation of niosomes as effective transdermal drug delivery systems. Eur J Pharm Biopharm. 2011;79(1):28-35.
134. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172(1-2):33-70.
135. Allam AN, Gamal SSE, Naggar VF. Formulation and evaluation of acyclovir niosomes for ophthalmic use. AJPBR. 2011;1(1):28-40.
136. Hashim F, El-Ridy M, Nasr M, Abdallah Y. Preparation and characterization of niosomes containing ribavirin for liver targeting. Drug Deliv. 2010 Jul;17(5):282-7.
137. Ravi Kumar MNV. A review of chitin and chitosan applications. Reactive and Functional Polymers. 2000;46(1):1-27.
138. Tang ESK, Huang M, Lim LY. Ultrasonication of chitosan and chitosan nanoparticles. Int J Pharm. 2003;265(1-2):103-14.
139. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Rel. 2004;100(1):5-28.
140. Dev A, Binulal NS, Anitha A, Nair SV, Furuike T, Tamura H, Jayakumar R. Preparation of poly(lactic acid)/chitosan nanoparticles for anti-HIV drug delivery applications. Carbohydrate Polymers. 2010;80(3):833-8.
141. Hasanovic A, Zehl M, Reznicek G, Valenta C. Chitosan-tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability. J Pharm Pharmacol. 2009;61(12):1609-16.
142. Rokhade AP, Patil SA, Aminabhavi TM. Synthesis and characterization of semi-interpenetrating polymer network microspheres of acrylamide grafted dextran and chitosan for controlled release of acyclovir. Carbohydrate Polymers. 2007;67(4):605-13.
143. Dhaliwal S, Jain S, Singh HP, Tiwary AK. Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. AAPS J. 2008 Jun;10(2):322-30.
144. Stulzer HK, Lacerda L, Tagliari MP, Silva MAS, Fávere VT, Laranjeira MCM. Synthesis and characterization of cross-linked malonylchitosan microspheres for controlled release of acyclovir. Carbohydrate Polymers. 2008;73(3):490-7.
145. Moon HJ, Lee JS, Talactac MR, Chowdhury MYE, Kim JH, Park ME, Choi YK, Sung MH, Kim CJ. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus. Vet Microbiol. (0).
146. Gupta NK, Tomar P, Sharma V, Dixit VK. Development and characterization of chitosan coated poly-(e{open}-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine. 2011;29(48):9026-37.
147. Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci. 2007;32(4-5):278-90.
148. Garg M, Asthana A, Agashe HB, Agrawal GP, Jain NK. Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics. J Pharm Pharm. 2006;58(5):605-16.
149. Kaur A, Jain S, Tiwary A. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharmaceutica. 2008;58(1):61-74.
150. Jain SK, Gupta Y, Jain A, Saxena AR, Khare P, Jain A. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomed Nanotechnol Biol Med. 2008;4(1):41-8.
151. Wang X, Matei E, Deng L, Ramstrom O, Gronenborn AM, Yan M. Multivalent glyconanoparticles with enhanced affinity to the anti-viral lectin Cyanovirin-N. Chem Commun (Camb). 2011 Aug 14;47(30):8620-2.
152. Kaur CD, Nahar M, Jain NK. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target. 2008;16(10):798-805.
153. Mishra V, Mahor S, Rawat A, Gupta PN, Dubey P, Khatri K, Vyas SP. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target. 2006;14(1):45-53.
154. Papp I, Sieben C, Ludwig K, Roskamp M, Bottcher C, Schlecht S, Herrmann A, Haag R. Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles. Small. 2010 Dec 20;6(24):2900-6.
155. Flasher D, Konopka K, Chamow SM, Dazin P, Ashkenazi A, Pretzer E, Düzgünes N. Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). Biochimica et Biophysica Acta (BBA) Biomembranes. 1994;1194(1):185-96.
156. Slepushkin VA, Salem II, Andreev SM, Dazin P, Düzgüneş N. Targeting of Liposomes to HIV-1-Infected Cells by Peptides Derived from the CD4 Receptor. Biochem Biophys Res Comm. 1996;227(3):827-33.
157. Clayton R, Ohagen A, Goethals O, Smets A, Van Loock M, Michiels L, Kennedy-Johnston E, Cunningham M, Jiang H, Bola S, Gutshall L, Gunn G, Del Vecchio A, Sarisky R, Hallenberger S, Hertogs K. Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1κ monoclonal antibody, in HIV-1 infected cells. J Virol Meth. 2007;139(1):17-23.
158. Clayton R, Ohagen A, Nicol F, Del Vecchio AM, Jonckers THM, Goethals O, Van Loock M, Michiels L, Grigsby J, Xu Z, Zhang YP, Gutshall LL, Cunningham M, Jiang H, Bola S, Sarisky RT, Hertogs K. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes. Antiviral Res. 2009;84(2):142-9.
159. Bronshtein T, Toledano N, Danino D, Pollack S, Machluf M. Cell derived liposomes expressing CCR5 as a new targeted drug-delivery system for HIV infected cells. J Control Rel. 2011;151(2):139-48.
160. Norley SG, Sendele D, Huang L, Rouse BT. Inhibition of herpes simplex virus replication in the mouse cornea by drug containing immunoliposomes. Invest Ophthalmol Vis Sci. 1987 March 1, 1987;28(3):591-5.
161. Munyendo WL, Lv H, Benza-Ingoula H, Baraza LD, Zhou J. Cell penetrating peptides in the delivery of biopharmaceuticals. Biomolecules. 2012;2(2):187-202.
162. Borgmann K, Rao KS, Labhasetwar V, Ghorpade A. Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons. AIDS Res Hum Retroviruses. 2011 Aug;27(8):853-62.
163. Wan L, Pooyan S, Hu P, Leibowitz M, Stein S, Sinko P. Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery. Pharm Res. 2007;24(11):2110-9.
164. Mahajan SD, Roy I, Xu G, Yong KT, Ding H, Aalinkeel R, Reynolds J, Sykes D, Nair BB, Lin EY, Prasad PN, Schwartz SA. Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles. Curr HIV Res. 2010 Jul;8(5):396-404.
165. Dutta T, Garg M, Jain NK. Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur J Pharm Sci. 2008;34(2-3):181-9.
166. Resnik DB, Tinkle SS. Ethical issues in clinical trials involving nanomedicine. Contemp Clin Trials. 2007 Jul;28(4):433-41.
167. Jones T, Flack M, Stanberry L, Baker JR, Jr. Safety, tolerance, pharmacokinetics, and efficacy of topical nanoemulsion (NB-001) for the treatment of herpes labialis. American Academy of Dermatology Annual Meeting; February 1-5, 2008; San Antonio, Texas, 2008.
168. Xie F-M, Zeng K, Chen ZL, Li GF, Lin ZF, Zhu XL, Sun LD. [Treatment of recurrent condyloma acuminatum with solid lipid nanoparticle gel containing podophyllotoxin: a randomized double-blinded, controlled clinical trial]. Nan Fang Yi Ke Da Xue Xue Bao. 2007;27(5):657-9.
169. Powers DC. Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults. Mechan Ageing Devel. 1997;93(1-3):179-88.
170. Makidon PE, Bielinska AU, Nigavekar SS, Janczak KW, Knowlton J, Scott AJ, Mank N, Cao Z, Rathinavelu S, Beer MR, Wilkinson JE, Blanco LP, Landers JJ, Baker JR Jr. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS ONE. 2008;3(8):e2954.